Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Sandoz
Pharma
J&J, Samsung Bioepis ink Stelara biosimilar settlement
Samsung Bioepis' biosimilar, which Sandoz has signed on to commercialize, can launch on Feb. 22, 2025, pending FDA approval.
Zoey Becker
Nov 30, 2023 4:48pm
AbbVie files patent litigation against generic Rinvoq makers
Nov 22, 2023 9:04am
In splitting from Novartis, Sandoz makes muted market debut
Oct 4, 2023 11:16am
Otsuka, Astellas, Exelixis and Insilico—Fierce Pharma Asia
Sep 15, 2023 9:00am
Sandoz inks deal to commercialize biosim to J&J's Stelara
Sep 11, 2023 11:45am
Novartis' knockoff of Biogen's Tysabri is first MS biosim in US
Aug 25, 2023 11:28am
